The perils of PCR: can we accurately 'correct' antimalarial trials?

Trends in Parasitology

Volumn 26, Issue 3, 2010, Pages 119-124

  Juliano, Jonathan J ^a   Gadalla, Nahla ^b,c   Sutherland, Colin J ^b,c   Meshnick, Steven R ^d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c HOSPITAL FOR TROPICAL DISEASES   (United Kingdom)

^d IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ; ARTESUNATE; ARTESUNATE PLUS FANSIDAR; ARTESUNATE PLUS MEFLOQUINE; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; FANSIDAR; FANSIDAR PLUS QUININE; GLUTAMATE RICH PROTEIN; MEFLOQUINE; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 2; PROTEIN; QUININE; UNCLASSIFIED DRUG;

ARTICLE; CAPILLARY ELECTROPHORESIS; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; GENETIC VARIABILITY; GENOTYPE; HETERODUPLEX ANALYSIS; HUMAN; MALARIA; MALARIA FALCIPARUM; NONHUMAN; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; REINFECTION; SINGLE STRAND CONFORMATION POLYMORPHISM; SOUTHERN BLOTTING; TREATMENT FAILURE;

ANTIMALARIALS; CLINICAL TRIALS AS TOPIC; HUMANS; MALARIA; POLYMERASE CHAIN REACTION;

EID: 76749100588     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2009.12.007     Document Type: Article

References (46)

1. Dondorp A.M., et al. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361 (2009) 455-467
2. Wongsrichanalai C., and Meshnick S.R. Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. Emerg. Infect. Dis. 14 (2008) 716-719
3. Borrmann, S. et al. (2008) Revisiting the design of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria. PLoS Med. 5, e227 DOI:10.1371/journal.pmed.0050227 (www.plosmedicine.org)
4. Sutherland, C.J. (2008) Comparing highly efficacious antimalarial drugs. PLoS Med. 5, e228 DOI:10.1371/journal.pmed.0050228 (www.plosmedicine.org)
5. Stepniewska K., and White N.J. Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Malar. J. 5 (2006) 127
6. Collins W.J., et al. The use of genotyping in antimalarial clinical trials: a systematic review of published studies from 1995-2005. Malar. J. 5 (2006) 122 Review
7. Snounou G., and Beck H.P. The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment. Parasitol. Today 14 (1998) 462-467
8. Viriyakosol S., et al. Genotyping of Plasmodium falciparum isolates by the polymerase chain reaction and potential uses in epidemiological studies. Bull. World Health Organ 73 (1995) 85-95
9. Greenhouse B., et al. Validation of microsatellite markers for use in genotyping polyclonal Plasmodium falciparum infections. Am. J. Trop. Med. Hyg. 75 (2006) 836-842
10. Juliano J.J., et al. Misclassification of drug failures in Plasmodium falciparum clinical trials in Southeast Asia. J. Infect. Dis. 200 (2009) 624-628
11. Kain K.C., et al. Single-strand conformational polymorphism analysis differentiates Plasmodium falciparum treatment failures from re-infections. Mol. Biochem. Parasitol. 79 (1996) 167-175
12. Kwiek J.J., et al. Estimating true antimalarial efficacy by heteroduplex tracking assay in patients with complex Plasmodium falciparum infections. Antimicrob. Agents Chemother. 51 (2007) 521-527
13. Ngrenngarmlert W., et al. Measuring allelic heterogeneity in Plasmodium falciparum by a heteroduplex tracking assay. Am. J. Trop. Med. Hyg. 72 (2005) 694-701
14. Nyachieo A., et al. Plasmodium falciparum genotyping by microsatellites as a method to distinguish between recrudescent and new infections. Am. J. Trop. Med. Hyg. 73 (2005) 210-213
15. Ohrt C., et al. Determination of failure of treatment of Plasmodium falciparum infection by using polymerase chain reaction single-strand conformational polymorphism fingerprinting. Clin. Infect. Dis. 28 (1999) 847-852
16. Daubersies P., et al. Rapid turnover of Plasmodium falciparum populations in asymptomatic individuals living in a high transmission area. Am. J.Trop. Med. Hyg. 54 (1996) 18-26
17. Farnert A., et al. Extensive dynamics of Plasmodium falciparum densities, stages and genotyping profiles. Malar. J. 7 (2008) 241
18. Jafari S., et al. Plasmodium falciparum clonal population dynamics during malaria treatment. J. Infect. Dis. 189 (2004) 195-203
19. Jafari-Guemouri S., et al. Plasmodium falciparum genotype population dynamics in asymptomatic children from Senegal. Microbes Infect. 8 (2006) 1663-1670
20. World Health Organization. Guidelines for the treatment of malaria (2006), World Health Organization, Geneva
21. World Health Organization. Methods and techniques for clinical trials on antimalarial drug efficacy: Genotyping to identify parasite populations (2007), World Health Organization
22. Juliano J.J., et al. Novel dhps and pfcrt polymorphisms in Plasmodium falciparum detected by heteroduplex tracking assay. Am. J. Trop. Med. Hyg. 80 (2009) 734-736
23. Juliano J.J., et al. Minority-variant pfcrt K76T mutations and chloroquine resistance, Malawi. Emerg . Infect. Dis. 13 (2007) 872-877
24. Juliano J.J., et al. Nonradioactive heteroduplex tracking assay for the detection of minority-variant chloroquine-resistant Plasmodium falciparum in Madagascar. Malar. J. 8 (2009) 47
25. Juliano J.J., et al. Detection of the dihydrofolate reductase-164L mutation in Plasmodium falciparum infections from Malawi by heteroduplex tracking assay. Am. J. Trop. Med. Hyg. 78 (2008) 892-894
26. Delwart E., et al. Homogeneous quasispecies in 16 out of 17 individuals during very early HIV-1 primary infection. Aids 16 (2002) 189-195
27. Harrington P.R., et al. Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course. Aids 23 (2009) 907-915
28. Schnell G., et al. Identification and recovery of minor HIV-1 variants using the heteroduplex tracking assay and biotinylated probes. Nucleic Acids Res. 36 22 (2008) e146 Epub 2008 Oct 23
29. Mugittu K., et al. Molecular genotyping in a malaria treatment trial in Uganda - unexpected high rate of new infections within 2 weeks after treatment. Trop. Med. Int. Health 12 (2007) 219-223
30. Wargo A.R., et al. Competitive release and facilitation of drug-resistant parasites after therapeutic chemotherapy in a rodent malaria model. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 19914-19919
31. Bruce M.C., et al. Cross-species interactions between malaria parasites in humans. Science 287 (2000) 845-848
32. Harrington W.E., et al. Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 9027-9032
33. Hastings I.M., et al. Malaria control and the evolution of drug resistance: an intriguing link. Trends Parasitol. 19 (2003) 70-73
34. Mercereau-Puijalon O., et al. Revisiting host/parasite interactions: molecular analysis of parasites collected during longitudinal and cross-sectional surveys in humans. Parasite Immunol. 18 (1996) 173-180
35. Sutherland C.J., et al. Novel pfdhps haplotypes among imported cases of Plasmodium falciparum malaria in the UK. Antimicrob. Agents Chemother. 53 (2009) 3405-3410
36. Sutherland C.J., et al. Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil. Malar. J. 7 (2008) 240
37. Humphreys G.S., et al. Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. Antimicrob. Agents Chemother. 51 (2007) 991-997
38. Sisowath C., et al. The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Trop. Med. Int. Health 12 (2007) 736-742
39. Greenhouse B., et al. Impact of transmission intensity on the accuracy of genotyping to distinguish recrudescence from new infection in antimalarial clinical trials. Antimicrob. Agents Chemother. 51 (2007) 3096-3103
40. Rogers W.O., et al. Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malar. J. 8 (2009) 10
41. Gatton M.L., and Cheng Q. Can estimates of antimalarial efficacy from field studies be improved?. Trends Parasitol. 24 (2008) 68-73
42. Slater M., et al. Distinguishing recrudescences from new infections in antimalarial clinical trials: major impact of interpretation of genotyping results on estimates of drug efficacy. Am. J. Trop. Med. Hyg. 73 (2005) 256-262
43. Curran J.M. An introduction to Bayesian credible intervals for sampling error in DNA profiles. Law, Probability and Risk 4 (2005) 115-126
44. Liljander A., et al. Optimization and validation of multi-coloured capillary electrophoresis for genotyping of Plasmodium falciparum merozoite surface proteins (msp1 and 2). Malar. J. 8 (2009) 78
45. Bushman F.D., et al. Massively parallel pyrosequencing in HIV research. Aids 22 (2008) 1411-1415
46. Wootton, D.G. et al. (2008) Open-label comparative clinical study of chlorproguanil-dapsone fixed dose combination (Lapdap) alone or with three different doses of artesunate for uncomplicated Plasmodium falciparum malaria. PLoS ONE 3, e1779 DOI:10.1371/journal.pone.0001779 (www.plosone.org)